Framework Agreement for Radiopharmaceuticals for Diagnostic Imaging and Biomedical Research

Summary

The National Centre for Cardiovascular Research Carlos III (CNIC) is establishing a single, non-lotted framework agreement for the supply of radiopharmaceuticals used in diagnostic imaging, nuclear medicine and biomedical research. Products include fluorine-18 fluorodeoxyglucose, technetium-99m sodium pertechnetate, technetium-99m sestamibi and equivalent or newly introduced radiopharmaceuticals. Supply will be ordered as needed at unit prices, with no minimum purchase commitment; the estimated framework value is €204,000 excluding VAT.